Elsevier

Journal of Electrocardiology

Volume 48, Issue 1, January–February 2015, Pages 8-9
Journal of Electrocardiology

QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation

https://doi.org/10.1016/j.jelectrocard.2014.10.005Get rights and content

Abstract

We assessed the feasibility of AliveCor tracings for QTC assessment in patients receiving dofetilide. Five patients with persistent AF underwent the two-handed measurement (mimicks Lead I). On the ECG, Lead I or II was used. There was no significant difference between the AliveCor-QTC and ECG-QTC (all ± 20 msec). The AliveCor device can be used to monitor the QTC in these patients.

References (3)

  • Tikosyn (dofetilide) home

There are more references available in the full text version of this article.

Cited by (70)

  • Can we predict sudden cardiac death?

    2023, Bulletin de l'Academie Nationale de Medecine
  • Use of Smartphones and Wearables for Arrhythmia Monitoring

    2021, Cardiac Electrophysiology Clinics
  • Remote Monitoring of the QT Interval and Emerging Indications for Arrhythmia Prevention

    2021, Cardiac Electrophysiology Clinics
    Citation Excerpt :

    These 3 studies concluded a good accuracy in the determination of QTc prolongation; however, 2 larger studies did not fully reproduce this positive result.20,21 In 2015 Chung and colleagues17 explored the possibility of using the AliveCor heart monitor to oversee the QTc changes in just 5 patients with atrial fibrillation taking dofetilide. They compared an AliveCor tracing for each patient with an ECG performed at approximately the same time that day.

View all citing articles on Scopus

This report contains data presented as an oral abstract at the 2014 American Heart Association Scientific Sessions in Chicago, Illinois.

View full text